The obesity-drug market in India is about to get a lot more crowded soon. And a lot cheaper. 

The tightly-guarded patent for semaglutide—the drug on whose back Novo Nordisk built the obesity-treatment industry—is about to expire in India.

Starting 21 March, the molecule behind the Danish pharma company’s blockbuster drugs, Wegovy and Ozempic, will lose its exclusivityThe legal, time-limited rights that prevent competitors from manufacturing, marketing, or selling a specific pharmaceutical product. Generic........

© The Ken